Pages that link to "Q35988425"

The following pages link to Helper role of NK cells during the induction of anticancer responses by dendritic cells (Q35988425):

Displaying 46 items.

• Exosomes as a tumor immune escape mechanism: possible therapeutic implications (Q21245472) (← links)
• Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination (Q26765345) (← links)
• Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity (Q27009908) (← links)
• Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase (Q33558482) (← links)
• DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor (Q33911460) (← links)
• Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist (Q33942806) (← links)
• Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro. (Q34066925) (← links)
• Role of the Innate Immune Response and Tumor Immunity Associated with Simian Virus 40 Large Tumor Antigen (Q34120703) (← links)
• CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells (Q34409830) (← links)
• The human T cell response to melanoma antigens (Q34587175) (← links)
• Helper Activity of Natural Killer Cells During the Dendritic Cell-mediated Induction of Melanoma-specific Cytotoxic T Cells (Q34672927) (← links)
• Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination (Q35839060) (← links)
• A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor (Q35849588) (← links)
• Immunotherapy of cancer in 2012. (Q36243536) (← links)
• TLR-dependent cross talk between human Kupffer cells and NK cells (Q36446960) (← links)
• Antitumor activity of NK cells (Q36751569) (← links)
• Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients (Q36806268) (← links)
• Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity (Q36868877) (← links)
• Are circadian rhythms the code of hypothalamic-immune communication? Insights from natural killer cells (Q36983795) (← links)
• Dendritic cell vaccination and immune monitoring. (Q37212802) (← links)
• Natural killer cells require selectins for suppression of subcutaneous tumors (Q37223426) (← links)
• NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses (Q37262370) (← links)
• Dendritic cells: a critical player in cancer therapy? (Q37276138) (← links)
• Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival (Q37299271) (← links)
• Oncolytic viruses: a novel form of immunotherapy (Q37300008) (← links)
• Integrating costimulatory agonists to optimize immune-based cancer therapies (Q37352989) (← links)
• DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. (Q37395354) (← links)
• Vaccination with live Leishmania major and CpG DNA promotes interleukin-2 production by dermal dendritic cells and NK cell activation (Q37410025) (← links)
• Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4 (Q37513871) (← links)
• Regulation of NK Cell Activation and Effector Functions by the IL-12 Family of Cytokines: The Case of IL-27. (Q37592689) (← links)
• Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy (Q37729135) (← links)
• Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors (Q37735454) (← links)
• Interferon-α in acute myeloid leukemia: an old drug revisited (Q37832939) (← links)
• Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system (Q38031222) (← links)
• NK cells: key to success of DC-based cancer vaccines? (Q38036202) (← links)
• Natural killer cells as helper cells in dendritic cell cancer vaccines (Q38352462) (← links)
• Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients (Q38890435) (← links)
• Separation methods of T cells, natural killer, and dendritic cells from peripheral blood of cancer patients using interleukin-2 and functional analysis of natural killer cells after separation (Q40140225) (← links)
• Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors (Q40339973) (← links)
• Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? (Q41520681) (← links)
• Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy (Q48381592) (← links)
• Integrated Nanovaccine with MicroRNA-148a Inhibition Reprograms Tumor-Associated Dendritic Cells by Modulating miR-148a/DNMT1/SOCS1 Axis (Q51639107) (← links)
• Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy. (Q52645997) (← links)
• Tumor immunotherapy: New aspects of natural killer cells. (Q55107050) (← links)
• Induction of myeloma-specific cytotoxic T lymphocytes responses by natural killer cells stimulated-dendritic cells in patients with multiple myeloma (Q84195559) (← links)
• Role of Dendritic Cells in Exposing Latent HIV-1 for the Kill (Q92441659) (← links)